Systolic Heart failure treatment with
the If inhibitor ivabradine Trial
Clinical profiles and outcomes of patients
with chronic heart failure and chronic
obstructive pulmonary disease: efficacy
and safety of ivabradine.
A SHIFT study analysis
Tavazzi L, et al. Int J Cardiol. 2013. Dec 10;170(2):182-188
www.shift-study.com
Effect of ivabradine on composite of
CV death or HF hospitalization
50
45
Patients (%)
40
COPD (placebo)
COPD (ivabradine)
35
30
Non-COPD (placebo)
Non-COPD (ivabradine)
25
20
15
10
5
0
0
6
12
18
24
Time (months)
Ivabradine is safe and effective in lowering the relative risk of the primary composite end
point in both COPD and non-COPD patients
Tavazzi L et al. Int J Cardiol. 2013. Dec 10;170(2):182-188
www.shift-study.com